Peptide-Receptor Interactions: A Primer

Almost every biological effect attributed to a peptide begins with a physical encounter: the peptide finds a receptor protein, binds to it, and changes that protein’s shape. Understanding peptide receptor binding is therefore the starting point for interpreting nearly any pharmacology experiment, from a simple competition assay to a cryo-electron microscopy structure. This primer covers how peptide ligands recognise their receptors, why so many peptide hormones act through G protein-coupled receptors (GPCRs), and how agonists, antagonists and partial agonists differ in mechanistic terms.

The glucagon-like peptide-1 receptor (GLP-1R) serves as a running example throughout. It is among the most thoroughly characterised peptide receptors, and studies of its native ligand, usually supplied as a synthetic GLP-1 research peptide, illustrate several general principles cleanly. The discussion stays at the level of molecular pharmacology and in-vitro measurement.

Ligands, receptors and the language of binding

A ligand is any molecule that binds specifically to a site on a target protein. For a receptor, binding is only half of the story: the receptor must also translate occupancy into a change in cellular state. Pharmacologists separate these two properties. Affinity describes how tightly a ligand binds, usually expressed as an equilibrium dissociation constant (K_d). Efficacy describes how effectively the bound ligand drives the receptor into an active conformation. Two peptides can share the same affinity yet produce very different responses, which is why binding data alone rarely settle a mechanistic question.

Peptide ligands differ from small molecules in ways that matter experimentally. They are larger, more flexible and usually make contact with the receptor across an extended surface rather than a single deep pocket. Many are unstructured in solution and adopt a defined conformation, often an α-helix, only when bound. Peptides are also susceptible to proteolysis, so the material actually present in an assay well may not match what was weighed out if protease activity is not controlled.

GPCRs and peptide hormones

GPCRs are seven-transmembrane proteins that couple ligand binding outside the cell to heterotrimeric G proteins inside it. They form the largest family of membrane receptors, and many peptide hormones and neuropeptides signal through them. The IUPHAR/BPS Guide to Pharmacology classifies GPCRs into classes; peptide receptors appear in both class A (rhodopsin-like) and class B.

Class B1 receptors and the two-domain model

Class B1, the secretin family, is made up almost entirely of receptors for peptide hormones of roughly 27 to 44 residues, including glucagon, GLP-1, glucose-dependent insulinotropic polypeptide (GIP), secretin, growth hormone-releasing hormone (GHRH) and calcitonin. These receptors have a large N-terminal extracellular domain (ECD) in addition to the transmembrane bundle. Binding is described by a two-domain model: the C-terminal portion of the peptide, typically helical, docks onto the ECD and provides much of the affinity, while the N-terminal portion inserts into the transmembrane core, where it triggers the conformational change that activates the receptor.

Truncating the N-terminus of a class B1 ligand often leaves substantial binding intact but removes or greatly reduces activation, producing a weak agonist or an antagonist.

GLP-1R as a worked example

GLP-1R binds the endogenous peptides GLP-1(7-36) amide and GLP-1(7-37). The receptor couples predominantly to G_s, activating adenylyl cyclase and raising intracellular cyclic AMP (cAMP), and it also recruits β-arrestins and undergoes agonist-driven internalisation. High-resolution cryo-EM structures of GLP-1R in complex with peptide agonists and G_s have shown the peptide’s N-terminus reaching deep into the transmembrane bundle, consistent with the two-domain model.

The native peptide also illustrates the stability problem described above. Dipeptidyl peptidase-4 (DPP-4) cleaves the N-terminal His-Ala dipeptide, yielding GLP-1(9-36) amide, which retains measurable binding but has greatly reduced agonist activity at GLP-1R. This is the two-domain model in action: remove the activation segment and much of the efficacy goes with it. Exendin-4, a peptide from Gila monster venom, is a potent GLP-1R agonist that resists DPP-4, and its N-terminally truncated form exendin(9-39) is widely used as a GLP-1R antagonist in experimental work.

Receptors built from more than one protein

Some peptide receptors are not a single polypeptide. The calcitonin receptor (CTR) can associate with receptor activity-modifying proteins (RAMP1, RAMP2 or RAMP3) to form the amylin receptors AMY₁, AMY₂ and AMY₃, each with its own ligand selectivity. Amylin analogues such as the acylated amylin analogue cagrilintide are therefore characterised against several receptor complexes, including CTR alone, rather than a single target. For experimental design, this means a cell line’s RAMP expression can change the apparent pharmacology of a peptide as much as the receptor itself does.

Agonists, antagonists and partial agonists

A full agonist produces the maximal response the system can generate. A partial agonist, even at saturating concentrations, produces a smaller maximal effect because it stabilises active receptor states less effectively. A neutral antagonist binds without changing the receptor’s activity and blocks agonist access, shifting the agonist concentration-response curve to the right. An inverse agonist reduces constitutive activity below baseline, a distinction visible only in systems where the receptor signals in the absence of ligand.

These categories are not fixed properties of a molecule. A ligand that behaves as a full agonist in a cell line that overexpresses the receptor can appear partial in a system with fewer receptors, because high receptor density amplifies weak efficacy. The same caution applies to functional selectivity, often called biased agonism: a ligand may activate G_s-cAMP signalling efficiently while recruiting β-arrestin weakly, or the reverse. GLP-1R has been a prominent system for biased agonism research, and published bias factors depend heavily on the reference agonist, cell background and assay chosen. Bias reported in a recombinant cell line is an in-vitro observation and does not by itself predict behaviour in tissue or in an animal.

Measuring peptide-receptor interactions

Binding is commonly measured with radioligand or fluorescent-ligand assays. Saturation experiments with a labelled peptide give K_d and receptor density (B_max), while competition experiments with an unlabelled peptide give an IC₅₀ that can be converted to an inhibition constant (K_i). Label-free methods such as surface plasmon resonance report association and dissociation rates directly, although purified, correctly folded GPCRs are difficult to work with. The relationships between K_d, K_i, IC₅₀ and EC₅₀ are covered in our guide to binding affinity.

Functional assays measure what happens after binding. For G_s-coupled peptide receptors, cAMP accumulation is the standard readout, and when testing native GLP-1 as a reference agonist researchers usually include a phosphodiesterase inhibitor so that cAMP is not degraded during the incubation. Other readouts include β-arrestin recruitment by BRET or enzyme complementation, calcium mobilisation for G_q-coupled receptors, and receptor internalisation. Each assay reports a different step in the pathway, so the potency of a peptide is assay-dependent; a later article on cell signaling assays covers these methods in more detail.

Whatever the readout, several controls apply. Peptide identity and purity should be confirmed by mass spectrometry and HPLC before concluding anything about activity, since a truncated or oxidised impurity can act as a partial agonist or antagonist. Nonspecific adsorption to plastic is significant for many peptides at low nanomolar concentrations, and carrier protein in the buffer reduces it, though albumin will also bind lipidated peptides and lower their free concentration. Parental cells lacking the receptor confirm that a signal is receptor-mediated.

Interpreting receptor data with care

Receptor pharmacology rewards precision about what was actually measured. A K_d describes binding under defined conditions; an EC₅₀ describes a response in a particular cell system; neither is a statement about effects in a whole organism. Findings from recombinant cell lines are in-vitro evidence, animal studies add pharmacokinetics and physiology but come with species differences in receptor sequence and distribution. Keeping these layers distinct, and reporting the receptor construct, cell background, reference ligand and assay conditions alongside every number, is what makes peptide receptor binding data reproducible and comparable across laboratories.

References

1. Rang, H. P., Ritter, J. M., Flower, R. J. and Henderson, G. Rang and Dale’s Pharmacology. Elsevier.
2. IUPHAR/BPS Guide to Pharmacology. International Union of Basic and Clinical Pharmacology and British Pharmacological Society. Online database.
3. Neubig, R. R. et al. International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacological Reviews, 2003.
4. Kenakin, T. A Pharmacology Primer: Techniques for More Effective and Strategic Drug Discovery. Academic Press.